We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
AVTX | Avalo Therapeutics Inc | 18.30 | 13.55 | 285.26% | 138,275 |
BCG | Binah Capital Group Inc | 21.00 | 11.50 | 121.05% | 10,724 |
SSKN | Strata Skin Sciences Inc | 0.66 | 0.2151 | 48.35% | 2 |
PIK | Kidpik Corporation | 4.19 | 0.92 | 28.13% | 25,769 |
AKBA | Akebia Therapeutics Inc | 2.86 | 0.62 | 27.68% | 736,432 |
LGVN | Longeveron Inc | 3.77 | 0.66 | 21.22% | 653 |
SVMH | SRIVARU Holding Ltd | 0.3165 | 0.0515 | 19.43% | 16,793 |
MGIH | Millennium Group International Holdings Ltd | 1.51 | 0.24 | 18.90% | 396 |
BRKH | BurTech Acquisition Corporation | 13.00 | 2.00 | 18.18% | 135 |
LFLY | Leafly Holdings Inc | 3.50 | 0.47 | 15.51% | 1 |
XXII | 22nd Century Group Inc | 0.1508 | 0.0193 | 14.68% | 100,230 |
Kidpik Corp. (NASDAQ: PIK) ("kidpik” or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that is has regained full compliance with the Minimum Bid Price Requirement.
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at ...
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
IGPK | Integrated Cannabis Solutions Inc | 436 | |
LWLG | Lightwave Logic Inc | 195 | |
FNMA | Fannie Mae | 118 | |
4 | FBEC | FBEC Worldwide Inc | 62 |
5 | RNVA | Rennova Health Inc | 76 |
6 | SPZI | SPOOZ Inc | 67 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,621.35 | 1,156.78 | 1.67% | 1.38T | 7,376,737,190 |
ETH | Ethereum | 3,575.19 | 75.13 | 2.15% | 429.25B | 3,937,733,128 |
USDT | Tether USD | 0.99961 | 0.00017 | 0.02% | 97.81B | 1,037,898,827 |
BNB | Binance Coin | 589.63 | 15.51 | 2.70% | 93.01B | 517,323,115 |
SOL | Solana | 187.90 | 1.74 | 0.93% | 82.44B | 1,821,036,200 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions